ArticleBMC biochemistry2014
Mammalian target of Rapamycin inhibition and mycobacterial survival are uncoupled in murine macrophages.
Article in BMC biochemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 47 citations in OpenAlex.
- Article
- mTORC1 inhibitors rapamycin and everolimus as host-directed therapy for tuberculosis.Infection and immunity · 2026Article
- ZebrafishLife science alliance · 2024Article
- Review
- Understanding CNS Effects of Antimicrobial Drugs Using Zebrafish Models.Veterinary sciences · 2023Review
- Survival of intracellular pathogens in response to mTORC1- or TRPML1-TFEB-induced xenophagy.Autophagy reports · 2023Article
- Chemical modulation of SQSTM1/p62-mediated xenophagy that targets a broad range of pathogenic bacteria.Autophagy · 2022Article
- FDA-Approved Amoxapine Effectively Promotes Macrophage Control of Mycobacteria by Inducing Autophagy.Microbiology spectrum · 2022Article
- Reversing BCG-mediated autophagy inhibition and mycobacterial survival to improve vaccine efficacy.BMC immunology · 2022Article
- Article
- Induced Synthesis of Mycolactone Restores the Pathogenesis ofFrontiers in immunology · 2022Article
- Host-Pathogen Interactions Operative duringImmune network · 2021Review
- Inhibition of autophagy promotes human RSV NS1-induced inflammation and apoptosisExperimental and therapeutic medicine · 2021Article
- Mycobacterium tuberculosis PE_PGRS20 and PE_PGRS47 Proteins Inhibit Autophagy by Interaction with Rab1A.mSphere · 2021Article
- Autophagy and Host Defense in Nontuberculous Mycobacterial Infection.Frontiers in immunology · 2021Review
- Autophagy as a Target for Drug Development Of Skin Infection Caused by Mycobacteria.Frontiers in immunology · 2021Review
- Understanding the Reciprocal Interplay Between Antibiotics and Host Immune System: How Can We Improve the Anti-Mycobacterial Activity of Current Drugs to Better Control Tuberculosis?Frontiers in immunology · 2021Review
- Identification of Autophagy-Inhibiting Factors of Mycobacterium tuberculosis by High-Throughput Loss-of-Function Screening.Infection and immunity · 2020Article
- Antimycobacterial Effects of Everolimus in a Human Granuloma Model.Journal of clinical medicine · 2020Article
- Looking beyond Typical Treatments for Atypical Mycobacteria.Antibiotics (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundAutophagy is a cellular response to intracellular pathogens including mycobacteria and is induced by the direct inhibitors of mammalian target of Rapamycin (mTOR), a major negative regulator of autophagy. Autophagy induction by mTOR inhibition (mTOR dependent autophagy), through chemical means or starvation, leads to mycobacterial killing in infected cells. However, previous work by our group has shown that mycobacterial infection of macrophages naturally induces both autophagy and mammalian target of Rapamycin (mTOR) activity (mTOR independent autophagy). In the current work, we further explore the relationship between mTOR activity and mycobacterial killing in macrophages.
resultsWhile low concentrations of the mTOR inhibitors, Rapamycin, Torin 1, and Torin 2, can effectively reduce or block mTOR activity in response to lipopolysaccharides (LPS) or mycobacteria, higher concentrations (10 uM) are required to observe Mycobacterium smegmatis killing. The growth of M. smegmatis was also inhibited by high concentrations of Rapamycin in LC3B and ATG5 deficient bone marrow derived macrophages, suggesting that non-autophagic mechanisms might contribute to killing at high doses. Since mycobacterial killing could be observed only at fairly high concentrations of the mTOR inhibitors, exceeding doses necessary to inhibit mTOR, we hypothesized that high doses of Rapamycin, the most commonly utilized mTOR inhibitor for inducing autophagic killing, may exert a direct bactericidal effect on the mycobacteria. Although a short-term treatment of mycobacteria with Rapamycin did not substantially affect mycobacterial growth, a long-term exposure to Rapamycin could impact mycobacterial growth in vitro in select species.
conclusionsThis data, coupled with previous work from our laboratory, further indicates that autophagy induction by mTOR inhibition is an artificial means to increase mycobacterial killing and masks more relevant endogenous autophagic biochemistry that needs to be understood.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.